Investor presentationSep 2026
Sep 2026 · PPT
Source: Bse
Procter & Gamble Health Limited (PGHL)
Small CapPharma stocks · Small cap · NSE
Procter & Gamble Health Limited operates in OTC Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals02 Oct 2026 · screener
Latest result06 Aug, 07:33 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags03 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
54Neutralfull bear SMA stack · SMA20 -5.4% / mo · MACD + · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 25
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
PGHLD candles · FIT view-0.1%Latest close ₹5135.50 on 2026-10-19
Bar
-1.3%
RSI
36
MACD hist
0.38
52W pos
19%
2026-10-19O ₹5204.50H ₹5211.50L ₹5105.50C ₹5135.50Vol 5,453 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
PGHLNifty PharmaNifty 500
- PGHL
- -25.1%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -19.5 pp
Chart stats
19 Oct 2026- From 52W high
- -26.4%
- 52W range position
- 19%
- ATR (14)
- 2.8%
- Volume vs 20D
- 0.42x
- Avg traded value
- ₹7.1 Cr
- 20D price channel
- ₹5,105.5 - ₹5,880
₹6,975
₹4,707 - ₹6,975
₹145.1
Latest completed session
20-session average
28.8% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE53
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good57
Revenue +7.4% · PAT +45.5% YoY
Technical
Neutral54
Price trend and sector-relative-strength timing.
Valuation
Legacy model-93.9%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence84
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Good · 57/100Rev +7% YoY · PAT +45% YoY · operating leverage · margin compression
Filed 06 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹364 Cr | +7.4% | -1.6% |
| EBITDA | ₹100 Cr | +11.1% | -26.5% |
| Operating margin | 27.0% | +0 bps | -1000 bps |
| PAT | ₹96 Cr | +45.5% | +1.1% |
| PAT margin | 26.4% | +690 bps | +69 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 26.70
- P/B
- 16.96
- EV/EBITDA
- 18.18
- Market Cap
- 8897.00Cr
Profitability
- ROE
- 61.90%
- ROCE
- 83.90%
- ROA
- 42.45%
- Dividend Y
- 2.89%
Growth (CAGR)
- Revenue 5Y
- 1.00%
- EPS 5Y
- 5.00%
- Revenue 3Y
- 8.00%
- EPS 3Y
- 19.00%
Balance Sheet
- Debt/Equity
- 0.02
- Interest Coverage
- 466.00×
- Altman Z
- 10.42
- Book Value
- 316.00
Cash Flow
- FCF Yield
- 3.81%
- FCF Positive Y
- 11/5
- OCF
- 338.00 Cr
- EPS TTM
- 214.99
Shareholding
- Promoter Hold
- 51.82%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 29%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,408+50.7% vs prev
Net Profit
₹ CrLatest: 327+39.7% vs prev
Return on Equity
%Latest: 62.3+42.9% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 36.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- Recent death cross (SMA50 crossed below SMA200).
- SMA20 falling (~5.7% over last month) — short-term momentum negative.
- RSI(14) at 36 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- 26% off 52W high · 9% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
42
RS percentile
Stage 1 Base / Transition
1M return
-6.7%
3M return
-25.1%
6M return
+0.1%
1Y return
-16.9%
RS 1D
-1
RS 20D
-2
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is 10.1% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +0.9% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 84.15-0.23%
RS vs Nifty 50084
Valuation & peers
U-Score 53 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 53 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Premium Compounder
Fundamental score breakdown
U band · FAIR VALUEValuation2/30
Growth7/25
Quality20/20
Balance Sheet11/15
Cash Flow8/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
53
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
53/100 · legacy band FAIR VALUE
Positive drivers
- FCF yield is supportive at 3.8%.
- Piotroski is strong at 8/9.
- Quality contributes 20/20 to the score.
Main drags
- Fair-value margin of safety is negative at -93.9%.
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Growth is weaker at 7/25; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
26.7
PB
17.0
EV/EBITDA
18.2
ROE
61.9%
ROCE
83.9%
FCF Yield
3.8%
Debt/Equity
0.0
MoS
-93.9%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
53
Previous: 53
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
-93.9%
Previous: -93.9%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
53
53
53
53
53
53
53
53
53
53
53
53
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹1,236.36
-315.4% MoS
Growth-justified P/E
12.3
Growth-justified Value
₹2,648.68
-93.9% MoS
PEG
3.34
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
SANOFI
Small
Sanofi India Limited
Pharmaceuticals
match 138
53
15.8
47.1%
-305%
FAIR VALUE
INNOVACAP
Small
Innova Captab Limited
Pharmaceuticals
match 137
48
42.6
13.7%
+17%
FAIR VALUE
BLISSGVS
Small
Bliss GVS Pharma Limited
Pharmaceuticals
match 137
39
51.4
11.8%
-8%
WATCHLIST
FDC
Small
FDC Limited
Pharmaceuticals
match 135
40
17.5
11.2%
-180%
WATCHLIST
NOVARTIND
Small
Novartis India Limited
Pharmaceuticals
match 134
40
49.7
11.6%
-8%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Procter & Gamble Health Limited operates in OTC Products, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
84Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 97th percentile of the scored universe and 95th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
16 docs text-extracted · 3 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
97th percentile
overall median 67 · Pharma: 95th pctile, median 70 · Small: 98th pctile, median 66
Evidence depth
Financial-only
16 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
90
strong · capital discipline
Results
79
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 3.5%.
- ▸11 years of positive FCF.
- ▸Debt/equity is 0.02.
Trust risks
- ▸No major Trust Lite risk flags.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Procter & Gamble Health Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportSep 2026
Sep 2026 · 59Th Annual General Meeting Of The Company 12 Aug - Annual Report 2025-26 and AGM notice; 59th AGM on September 3, 2026.
Source: Bse
Investor presentation
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 18 Jun - Procter & Gamble Health shared FY2025-26 investor presentation; sales rose 16% and PAT 30%.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2026 from bse
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.